Evelo Biosciences Provides Updated Guidance on Advancing Clinical Inflammation Programs
April 14, 2022 06:00 ET
|
Evelo Biosciences, Inc.
–Guidance on registration trials for EDP1815 in psoriasis expected in 3Q 2022––Data from initial cohort of patients in Phase 2 trial of EDP1815 in atopic dermatitis expected 1Q 2023––Faster release...
European Dermatology Excimer Laser Industry to 2027 - Key Drivers and Challenges
April 14, 2022 05:43 ET
|
Research and Markets
Dublin, April 14, 2022 (GLOBE NEWSWIRE) -- The "Europe Dermatology Excimer Laser Market By Product, By Application, By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027" report has...
Evelo Biosciences Announces Appointments of Jose-Carlos Gutiérrez-Ramos and Tonya Williams to Board of Directors
April 06, 2022 06:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today...
Dermatology OTC Medications Market Worth $21.31Bn, Globally, by 2028 at 4.7% CAGR - Exclusive Report by The Insight Partners
March 25, 2022 06:46 ET
|
The Insight Partners
New York, March 25, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Dermatology OTC Medications Market Forecast to 2028 - COVID-19 Impact and Global Analysis By...
National Survey Reveals Insights into Emotional Impact of Psoriasis and Illuminates Need for New Topical Treatments
March 22, 2022 08:00 ET
|
Arcutis Biotherapeutics, Inc.
64% of adults with plaque psoriasis who are on topical treatments reported ever having psoriasis in intertriginous areas, higher than previous epidemiological studies suggestAround three in four...
Mindera Health™ Appoints Ted St. Martin as Chief Financial Officer
March 10, 2022 08:00 ET
|
Mindera Health
San Diego, CA, March 10, 2022 (GLOBE NEWSWIRE) -- Mindera Health™, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of precision medicine in psoriasis, ...
Mindera Health™ Appoints Deborah L. Rice-Johnson to its Board of Directors
March 01, 2022 08:00 ET
|
Mindera Health
San Diego, CA, March 01, 2022 (GLOBE NEWSWIRE) -- Mindera Health™, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in...
Inventiva reçoit un paiement d'étape de 4 M€ de la part d’AbbVie suite au lancement de l’étude de Phase IIb avec cedirogant
January 31, 2022 16:00 ET
|
INVENTIVA
Daix (France), Long Island City (New York), Etats-Unis, le 31 janvier 2022 – Inventiva S.A. (« Inventiva » ou la « Société ») (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée...
Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiation
January 31, 2022 16:00 ET
|
INVENTIVA
Daix (France), Long Island City (New York, United States), January 31, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral...
Mindera Health™ and WellDyne announce a definitive agreement to improve management of moderate-to-severe psoriasis patients
January 04, 2022 11:00 ET
|
Mindera Health
SAN DIEGO, CA and LAKELAND, FL, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Mindera Health™ and WellDyne have entered into a definitive agreement to improve the management of psoriasis patients with moderate...